Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | KIF11 | P52732 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13199189 | 0.88 | ACSS2 (0.51) | ACSS2POLBNPSR1HPGDALDH1A1 | |
| SCHEMBL28653814 | 0.85 | NPSR1 (0.45) | ACSS2POLBNPSR1ALDH1A1CES2 | |
| SCHEMBL31306494 | 0.83 | NPSR1 (0.50) | ACSS2POLBNPSR1HPGDALDH1A1 | |
| SCHEMBL2012390 | 0.83 | ACSS2 (0.48) | ACSS2POLBNPSR1KIF11CES2 | |
| SCHEMBL30628323 | 0.83 | ACSS2 (0.48) | ACSS2POLBNPSR1KIF11CES2 | |
| SCHEMBL17420423 | 0.82 | POLB (0.51) | ACSS2POLBNPSR1ALDH1A1LMNA | |
| SCHEMBL17420520 | 0.82 | ACSS2 (0.47) | ACSS2POLBNPSR1HPGDALDH1A1 | |
| SCHEMBL12003891 | 0.81 | MAOB (0.47) | MAOBACSS2POLBNPSR1HPGD | |
| SCHEMBL26017812 | 0.81 | ACSS2 (0.41) | ACSS2POLBNPSR1HPGDALDH1A1 | |
| SCHEMBL1657919 | 0.81 | ACSS2 (0.46) | ACSS2POLBNPSR1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| US-12419962-B2 | Quinazolines, pharmaceutical compositions, and therapeutic applications | BIOTHERYX, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250270220-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12304915-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-05-20 | — | — | US | disclosed |
| WO-2025070947-A1 | NOVEL PHTHALAZINE DERIVATIVE COMPOUND AS SOS1 INHIBITOR, AND USE THEREOF | 한미약품 주식회사 | 2025-04-03 | — | — | WO | disclosed |
| CN-119462626-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240400518-A1 | SOS1 INHIBITOR AND USE THEREOF | CYRUS THERAPEUTICS INC. (KR) | 2024-12-05 | — | — | US | disclosed |
| CN-115135315-B | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| US-20240208945-A1 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | MEDSHINE DISCOVERY INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4389738-A1 | SOS1 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-06-26 | — | — | EP | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| WO-2023029833-A1 | SOS1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海海和药物研究开发股份有限公司 | 2023-03-09 | — | — | WO | disclosed |
| WO-2023022497-A1 | SOS1 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-02-23 | — | — | WO | disclosed |
| EP-4076418-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115135315-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| WO-2022199670-A1 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | 南京明德新药研发有限公司 | 2022-09-29 | — | — | WO | disclosed |
| CN-113727758-A | Bicyclic heterocyclic compounds and use thereof | 锐新医药公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20210188857-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| US-20210188857-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| WO-2021127429-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419962-B2 | Quinazolines, pharmaceutical compositions, and therapeutic applications | RAB1A, SOS1, IQGAP1 | MAOB 1842/4885ACSS2 2108/4885POLB 4577/4885 |
| US-12304915-B2 | SOS1 inhibitors | SOS1, SOS2, SAV1 | MAOB 3798/4885ACSS2 1497/4885POLB 3766/4885 |
| US-20230137886-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | MAOB 3798/4885ACSS2 1497/4885POLB 3766/4885 |
| US-20240208945-A1 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | CYP3A7, UGT2B7, CYP51A1 | MAOB 2443/4885ACSS2 673/4885POLB 3068/4885 |
| US-20250270220-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | MAOB 3798/4885ACSS2 1497/4885POLB 3766/4885 |
| US-20240400518-A1 | SOS1 INHIBITOR AND USE THEREOF | SOS1, RAC1, SOS2 | MAOB 3459/4885ACSS2 3283/4885POLB 4445/4885 |
| US-20210188857-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | MAOB 3811/4885ACSS2 2029/4885POLB 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.